Yan Kong

5.8k total citations
140 papers, 2.7k citations indexed

About

Yan Kong is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Yan Kong has authored 140 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Oncology, 61 papers in Molecular Biology and 28 papers in Immunology. Recurrent topics in Yan Kong's work include Cutaneous Melanoma Detection and Management (37 papers), CAR-T cell therapy research (30 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Yan Kong is often cited by papers focused on Cutaneous Melanoma Detection and Management (37 papers), CAR-T cell therapy research (30 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Yan Kong collaborates with scholars based in China, United States and Ethiopia. Yan Kong's co-authors include Lu Si, Jun Guo, Chuanliang Cui, Xinan Sheng, Zhihong Chi, Bin Lian, Jie Dai, Lili Mao, Dayong Wang and Bixia Tang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Yan Kong

134 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yan Kong China 34 1.3k 1.1k 511 370 322 140 2.7k
Weina Chen United States 35 801 0.6× 1.7k 1.6× 567 1.1× 620 1.7× 190 0.6× 221 4.2k
Qi Yang China 35 739 0.6× 2.1k 1.9× 377 0.7× 990 2.7× 463 1.4× 161 3.5k
Maria Tzardi Greece 32 1.2k 1.0× 677 0.6× 530 1.0× 356 1.0× 497 1.5× 143 3.1k
Yue Zhao China 33 814 0.6× 2.1k 1.9× 785 1.5× 1.5k 4.0× 994 3.1× 115 4.6k
Jing Nie China 37 1.5k 1.2× 2.0k 1.8× 661 1.3× 889 2.4× 221 0.7× 162 4.1k
Frank Antonicelli France 33 321 0.3× 780 0.7× 507 1.0× 375 1.0× 309 1.0× 75 3.1k
Yun Yang China 26 850 0.7× 1.5k 1.3× 194 0.4× 832 2.2× 258 0.8× 86 2.7k
Ke Liang China 29 1.2k 1.0× 2.0k 1.8× 272 0.5× 925 2.5× 454 1.4× 79 3.3k
Jia Li China 33 577 0.5× 1.6k 1.5× 229 0.4× 1.0k 2.7× 647 2.0× 138 3.1k
Wei Yao China 31 648 0.5× 1.2k 1.1× 540 1.1× 646 1.7× 266 0.8× 121 2.6k

Countries citing papers authored by Yan Kong

Since Specialization
Citations

This map shows the geographic impact of Yan Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Kong more than expected).

Fields of papers citing papers by Yan Kong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Kong. The network helps show where Yan Kong may publish in the future.

Co-authorship network of co-authors of Yan Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Kong. A scholar is included among the top collaborators of Yan Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Kong. Yan Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Fenghao, Qian Guo, Zhihong Chi, et al.. (2025). Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. Journal of genetics and genomics. 52(4). 525–538. 2 indexed citations
2.
Wu, Liang, Jun Li, Yan Kong, et al.. (2024). MA05.03 A Phase II Study of Tislelizumab Combined with Chemotherapy in Patients with Thymic Carcinoma. Journal of Thoracic Oncology. 19(10). S69–S69. 2 indexed citations
3.
Mao, Lili, Jie Dai, Xue Bai, et al.. (2024). Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study.. Journal of Clinical Oncology. 42(16_suppl). e21527–e21527. 1 indexed citations
4.
Guo, Qian, Jianjian Zhang, Yaling Huang, et al.. (2023). A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma. Cancer Research. 83(22). 3783–3795. 11 indexed citations
5.
Li, Ling, Yan Kong, Yu Bao, et al.. (2023). Vitamin D-binding protein in plasma microglia-derived extracellular vesicles as a potential biomarker for major depressive disorder. Genes & Diseases. 11(2). 1009–1021. 15 indexed citations
6.
Xiao, Xu, Qian Guo, Chuanliang Cui, et al.. (2022). Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. SHILAP Revista de lepidopterología. 2(1). 131–131. 18 indexed citations
7.
Cui, Chuanliang, Xuan Wang, Bin Lian, et al.. (2022). OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study. Journal for ImmunoTherapy of Cancer. 10(4). e004307–e004307. 38 indexed citations
8.
Li, Siming, Xiaowen Wu, Xieqiao Yan, et al.. (2022). Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for ImmunoTherapy of Cancer. 10(2). e004036–e004036. 33 indexed citations
9.
Fang, Hongwei, Zhun Sun, Zhouyi Chen, et al.. (2022). Bioinformatics and systems-biology analysis to determine the effects of Coronavirus disease 2019 on patients with allergic asthma. Frontiers in Immunology. 13. 988479–988479. 8 indexed citations
10.
Shang, Qingfeng, Xiaowen Wu, Qian Guo, et al.. (2022). FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma. Journal of Experimental & Clinical Cancer Research. 41(1). 170–170. 13 indexed citations
11.
Li, Wenjing, Zhumei Cui, Yan Kong, Xiangyu Liu, & Xiangyu Wang. (2021). Serum Levels of S100A11 and MMP‐9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance. BioMed Research International. 2021(1). 7341247–7341247. 10 indexed citations
12.
Wang, Xiangyu, et al.. (2021). Clinical analysis of 12 cases of ovarian cystic mature teratoma with malignant transformation into squamous cell carcinoma. Journal of International Medical Research. 49(2). 1220781101–1220781101. 6 indexed citations
13.
Yan, Xieqiao, Xinan Sheng, Zhihong Chi, et al.. (2021). Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. Journal of Clinical Oncology. 39(8). 881–889. 36 indexed citations
14.
Cui, Chuanliang, Wenxian Yang, Zhihong Chi, et al.. (2021). Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. npj Genomic Medicine. 6(1). 7–7. 61 indexed citations
15.
Hu, Jing, Chuanliang Cui, Wenxian Yang, et al.. (2020). Using deep learning to predict anti-PD-1 response in melanoma and lung cancer patients from histopathology images. Translational Oncology. 14(1). 100921–100921. 48 indexed citations
16.
Wang, Ling, Jingjing Liu, Yan Kong, Lihua Hou, & Yuhua Li. (2017). Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice. Human Gene Therapy. 29(1). 87–95. 6 indexed citations
17.
Liu, Jing, Xijun Liang, Danxia Zhou, et al.. (2016). Coupling of mitochondrial function and skeletal muscle fiber type by a miR‐499/Fnip1/ AMPK circuit. EMBO Molecular Medicine. 8(10). 1212–1228. 99 indexed citations
18.
Li, Ke, Yan Kong, Mingliang Zhang, et al.. (2016). Differentiation of pluripotent stem cells for regenerative medicine. Biochemical and Biophysical Research Communications. 471(1). 1–4. 24 indexed citations
19.
Wang, Chao, Chao Wan, Wenjuan Li, et al.. (2015). miR‐184 is Critical for the motility‐related PNS development in Drosophila. International Journal of Developmental Neuroscience. 46(1). 100–107. 10 indexed citations
20.
Lian, Bin, Lu Si, Chuanliang Cui, et al.. (2013). Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. Clinical Cancer Research. 19(16). 4488–4498. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Weina Chen Breakdown of academic impact, for papers by Qi Yang Breakdown of academic impact, for papers by Maria Tzardi Breakdown of academic impact, for papers by Yue Zhao Breakdown of academic impact, for papers by Jing Nie Breakdown of academic impact, for papers by Frank Antonicelli Breakdown of academic impact, for papers by Yun Yang Breakdown of academic impact, for papers by Ke Liang Breakdown of academic impact, for papers by Jia Li Breakdown of academic impact, for papers by Wei Yao
Rankless by CCL
2026